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Abstract 
Background: Malaria remains a challenging and fatal infectious disease in developing nations and the urgency for 
the development of new drugs is even greater due to the rapid spread of anti‑malarial drug resistance. While numer‑
ous parasite genetic, protein and metabolite biomarkers have been proposed for testing emerging anti‑malarial 
compounds, they do not universally correspond with drug efficacy. The biophysical character of parasitized cells is a 
compelling alternative to these conventional biomarkers because parasitized erythrocytes become specifically rigidi‑
fied and this effect is potentiated by anti‑malarial compounds, such as chloroquine and artesunate. This biophysical 
biomarker is particularly relevant because of the mechanistic link between cell deformability and enhanced splenic 
clearance of parasitized erythrocytes.
Methods: Recently a microfluidic mechanism, called the multiplexed fluidic plunger that provides sensitive and 
rapid measurement of single red blood cell deformability was developed. Here it was systematically used to evaluate 
the deformability changes of late‑stage trophozoite‑infected red blood cells (iRBCs) after treatment with established 
clinical and pre‑clinical anti‑malarial compounds.
Results: It was found that rapid and specific iRBC rigidification was a universal outcome of all but one of these drug 
treatments. The greatest change in iRBC rigidity was observed for (+)‑SJ733 and NITD246 spiroindolone compounds, 
which target the Plasmodium falciparum cation‑transporting ATPase ATP4. As a proof‑of‑principle, compounds of the 
bisindole alkaloid class were screened, where cladoniamide A was identified based on rigidification of iRBCs and was 
found to have previously unreported anti‑malarial activity with an IC50 lower than chloroquine.
Conclusion: These results demonstrate that rigidification of iRBCs may be used as a biomarker for anti‑malarial drug 
efficacy, as well as for new drug screening. The novel anti‑malarial properties of cladoniamide A were revealed in a 
proof‑of‑principle drug screen.
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Background
Malaria remains one of the greatest threats to human 
health. In 2013, there were an estimated 198 million 
cases resulting in 584,000 deaths [1], of which 90  % 
occurred in children under the age of five [2]. A number 
of effective anti-malarial drugs and derivatives have been 
developed. However, the emergence of drug-resistance 
[3] has prompted the urgent development of new anti-
malarial compounds as well as protocols to screen these 
compounds. Existing methods to screen for anti-malar-
ial activity are almost entirely based on parasite sur-
vival during the intra-erythrocytic stage and is typically 
assessed by microscopy, ELISA-based parasite antigen 
detection, fluorescent DNA-binding dyes, flow cytom-
etry, and PCR of parasite-specific genes [4]. However, the 
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measurement of parasite survival provides limited insight 
into the effectiveness of the candidate drug in vivo, there-
fore, requiring a large sub-set of compounds to be sub-
sequently evaluated using Plasmodium berghei in murine 
infection models, using a malarial species different from 
those that infect humans. Subsequent human clinical tri-
als are costly and are complicated by issues such as tox-
icity, bioavailability, patient physiology, and side-effects, 
resulting in extremely low success rates, even for com-
pounds that showed high efficacy in vitro [5]. Owing to 
the poor success of existing screening methods, there is a 
need for in vitro screens that align with a common mode 
of action for anti-malarial compounds in vivo. This type 
of in vitro method would significantly reduce the burden 
of animal and human drug trials.
Specific reduced deformability of Plasmodium falci-
parum parasitized red blood cells (iRBCs) has been well 
documented. This biophysical change has been attributed 
to oxidative stress induced by the parasites’ metabolism 
of haemoglobin [6], remodelling of the iRBC cytoskele-
ton by parasite-derived proteins [7], as well as the pres-
ence of the enlarged digestive vacuole in the late stages of 
infection [8, 9]. Interestingly, this rigidification of iRBCs 
enhances their accumulation in micro-anatomical zones 
and the microcirculation of the spleen, and contributes to 
their splenic elimination [10]. Furthermore, anti-malarial 
drugs are likely to exaggerate iRBCs’ rigidification and 
subsequent splenic clearance, by preventing haemoglobin 
detoxification or increasing intracellular oxidation [11, 
12]. Together, these observations suggest that enhanced 
splenic clearance of iRBCs due to their rigidification 
might contribute to the mode of action of anti-malarial 
compounds and would therefore be an important, clini-
cally relevant biomarker for drug efficacy.
Previous studies have reported infection-induced rigid-
ification of iRBCs following exposure to chloroquine or 
artesunate [13, 14]. However, parasitized cells may rep-
resent a small fraction of the erythrocyte population and 
this effect may not be detectable by conventional infer-
ence of average RBC deformability, based on the viscous 
properties of blood [15]. The microfluidic multiplexed 
Fluidic Plunger (MFP) overcomes this limitation by high-
throughput measurement of single-cell deformation 
through microstructures that mimic capillaries in the 
microvasculature.
The current study aimed to determine whether changes 
in iRBC deformability correlate with anti-malarial effi-
cacy. It was observed that iRBC rigidification was a 
common outcome of the anti-malarial drugs tested. Fur-
thermore, PfATP4 inhibitors that induce rapid clearance 
of parasitized cells induced the greatest magnitude of 
iRBC deformability. Finally, in a small screen of bisindole 
alkaloid compounds, it was shown that changes in iRBC 
deformability could predict the previously unreported 
anti-malarial properties of cladoniamide A.
Methods
Cultivation of Plasmodium falciparum 3D7
Type A+ blood was collected from healthy donors with 
written informed consent and approval from the UBC 
Office of Research Ethics (Network Centre for Applied 
Development, Canadian Blood Services). Washed eryth-
rocytes were then used to culture P. falciparum parasites 
(strain 3D7) (Network Centre for Applied Development, 
Canadian Blood Services) at 5 % haematocrit in culture 
media, consisting of RPMI-1640 medium (Invitrogen, 
CA, USA) containing 25 mM HEPES (Sigma-Aldrich, St 
Louis, MO, USA), 0.5 % AlbuMAX I (w/v) (Invitrogen), 
100 µM hypoxanthine (Sigma-Aldrich), 12.5 µg/ml gen-
tamicin (Invitrogen) and 1.77  mM sodium bicarbonate 
(Sigma-Aldrich) at pH 7.4. Cultures were grown in stand-
ard 90  mm Petri dishes (Corning Life Science, Tewks-
bury, MA, USA) at a final volume of 10 ml and were kept 
in a hypoxic incubator (Caron, Marietta, USA) with a 
standard gas environment of 5 % CO2, 1 % O2, and 94 % 
N2 at 37 °C.
Purification of iRBCs and subsequent drug treatment
A magnetic purification stand was fabricated based on 
the design by Kim [16] with some modifications to fit 
super magnets. LS columns (Miltenyi Biotec, Bergisch 
Gladbach, Germany) were employed in the positive selec-
tion of haemozoin-containing iRBCs (late-stage tropho-
zoite-iRBCs) by loading 30 ml of parasite culture at 2 % 
haematocrit (v/v) and 5–15  % parasitaemia. Washing 
media was prepared that was identical to culture media, 
with the exception of sodium bicarbonate. The columns 
were washed once with 5 ml washing media and the cap-
tured cells were eluted in another 5 ml washing media by 
centrifugation at 350×g for 5 min with no brakes. Enrich-
ment purity of late-stage trophozoite-iRBCs was deter-
mined Giemsa-staining of an aliquot (Sigma-Aldrich). 
The remaining cells were suspended in culture media and 
acclimatized for 30 min within a hypoxic chamber, prior 
to incubation with drugs at specified concentrations and 
incubation times. Anti-malarial compounds were diluted 
in DMSO to a normalized concentration four times 
greater than their established EC50 [17–20], as indicated 
in Table 1. The EC50 for each candidate anti-malarial drug 
was not known a priori, so they were each tested at a 
concentration of 1 µM. RBCs from healthy donors were 
evaluated, incubated with 0.01  % DMSO or ddH2O, as 
well as each compound to assess whether the observed 
effect was specific for iRBCs. RBC deformability was 
determined by multiplexed fluidic plunger and normal-
ized to the control DMSO-treated RBCs.
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Microfluidic measurements of iRBC deformability
The deformability of iRBCs was measured using the pre-
viously developed multiplexed fluidic plunger micro-
fluidic device (Fig.  1a, b) [21]. Briefly, the principle of 
the fluidic plunger mechanism involves infusing a single 
cell into a microchannel containing a constriction small 
enough to significantly deform the cell. When the cell is 
free flowing in the constriction, pressure applied across 
the microchannel is distributed along its length. Once 
the cell reaches the constriction, it forms a temporary 
seal against the constriction, causing the applied pres-
sure to focus across the cell. Precisely controlling the 
applied pressure allows an adjustable stress to be applied 
remotely to a cell and constriction pair. For the experi-
ments described in this study, a microchannel of 2.5 µm 
in width and 3.7  µm in thickness was used in order to 
constrain RBCs in a flat configuration parallel with the 
microchannel. A constriction aperture of 2.5  µm was 
used to constrain the RBCs and deformed them using 
pressure applied across the microchannel.
Multiplexing this process involves arranging multiple 
deformation microchannels in parallel, as well as design-
ing supporting microchannels that ensure that a consist-
ent pressure is applied to all microchannels independent 
of position and whether they are occupied by a RBC. 
These supporting microchannels consist of a rectangular 
detour around parallel deformation, along with longer 
microchannels leading to the sample inlet and outlet. The 
rectangular detour structure performs three key func-
tions: (1) pressure applied across the deformation micro-
channels derives from pressure applied across the inlet 
and outlet and is reduced by a precise ratio that is set by 
the relative length of the inlet microchannel and part of 
the rectangular detour; (2) pressure applied across the 
deformation microchannels is independent of position 
in the deformation microchannel array by the symmet-
ric fluidic structure of the rectangular detour; and, (3) 
pressure applied across the deformation microchannel is 
made independent of the number of cells being deformed 
by the relative hydrodynamic resistance of the deforma-
tion microchannels and the rectangular detour micro-
channel. Detailed technical design of the deformation 
microchannels and the rectangular detour are described 
in Myrand-Lapierre et  al. [21] The device used for this 
study consists of 34 deformation microchannels in paral-
lel with a rectangular detour microchannel of 25  µm in 
thickness and 250 µm in width.
In vitro drug sensitivity test by the SYBR green I assay
In vitro parasitized erythrocyte cultures were main-
tained such that the proportion of ring-stage parasites 
never exceeded 70  % and a parasitaemia of 5–8  % was 
established prior to drug sensitivity assay. The cells were 
collected by centrifugation at 350×g for 5  min and re-
suspended in RPMI culture media to a parasitaemia of 
0.5 %, and the haematocrit was adjusted to 2 % with fresh 
unparasitized RBCs. Parasitized RBCs were transferred 
to a 96-well culture plate (Corning, NY, USA) at 200 μl/
well of 0.5 % parasitized RBCs, at 2 % haematocrit. Each 
compound was added to the specified concentration 
(Table 1) and incubated in a hypoxic incubator at 37  °C 
(5  % O2, 5  % CO2, 90  % N2) for 24  h. Uninfected RBCs 
treated with 0.01 % DMSO (Sigma-Aldrich) and each test 
compound while iRBCs were also treated with 0.01  % 
DMSO alone, as controls. Following incubation, the 
plates were frozen and stored at −80  °C. Prior to assay, 
samples were thawed for 1  h at room temperature and 
mixed by pipetting. A total of 100 μl of each culture was 
Table 1 Individual concentrations and deformability values that were normalized to DMSO or ddH2O control for respec-
tive anti-malarial drug treatments
Drug name Concentration  
(≥4 × EC50)
Median normalized  
deformability
% Median increase  
in deformability
P value
Chloroquine 1 µM 1.41 41 <0.0001
Mefloquine 1 µM 1.22 22 0.0002
Pyrimethamine 20 nM 1.80 80 <0.0001
Proguanil 100 µM 1.58 58 0.0052
Artesunate 10 nM 1.29 29 0.0022
Artemether 8 nM 1.95 95 <0.0001
Dihydroartemisinin 20 nM 2.11 111 <0.0001
Tetracycline 100 µM 0.93 −7 ns
Atovaquone 250 nM 1.46 46 0.0001
(+)‑SJ733 1.08 µM 5.54 454 <0.0001
(−)‑SJ733 1.08 µM 0.90 −10 ns
NITD246 3.6 nM 3.34 234 <0.0001
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mixed with 100 μl of 1× SYBR in 2× Lysis buffer [20 mM 
Tris; 0.008 % Saponin (w/v); 0.08 % Triton X-100 (w/v)] 
and transferred to a new 96-well plate. Fluorescence sig-
nal was determined in duplicate using a Biomek FX Mul-
timode Detector (Beckman Coulter, Pasadena, CA, USA) 
at an excitation wavelength of 485  nm and an emission 
wavelength of 535 nm.
Statistical analysis
Median RBC deformability and interquartile range (IQR) 
was calculated using Graphpad Prism v5. A Student t 
test was used to assess statistical significance between 
normally distributed RBC deformability profiles. The 
relationship between changes in RBC deformability and 
anti-malarial drug incubation time or concentration was 
evaluated by linear regression, while non-linear regres-
sion analysis was used to analyse the in vitro IC50 of new 
compounds on parasites.
Results
Multiplexed fluidic plunger detected time‑dependent 
rigidification of chloroquine‑treated iRBCs
Alteration in RBC deformability after P. falciparum infec-
tion and anti-malarial drug treatment was assessed using 
the MFP device [21], which measures the deformability 
of single RBCs based on the pressure required to transit 
a funnel-shaped microconstriction (Fig.  1). To evaluate 
the sensitivity of this system for measuring drug-induced 
changes in RBC deformability, the deformability of puri-
fied P. falciparum 3D7 iRBCs was determined over a 
range of chloroquine concentrations by measuring the 
median transit pressure through a microscale funnel 
(Fig.  2a). While chloroquine did not affect the median 
transit pressure for uninfected RBCs (Additional file  1: 
Figure S1), iRBCs required significantly greater transit 
pressure at 1 µM (p = 0.0002) and 1.5 µM (p = 0.0006) of 
chloroquine treatment, compared to untreated controls. 
Both untreated and chloroquine-treated iRBCs showed 
a time-dependent rigidification. However, following 
4  h of incubation, the chloroquine-treated iRBCs were 
significantly more rigid than untreated iRBCs (Fig.  2b, 
p = 0.0026). Furthermore, there is a direct linear corre-
lation between chloroquine incubation time and iRBC 
transit pressure (Fig. 2c, R2 = 0.9784).
Measurement of iRBC deformability following treatment 
with a panel of conventional anti‑malarial compounds
Previous studies have reported that both chloroquine and 
artesunate treatment contribute to a specific rigidifica-
tion of iRBCs [13, 14]. However, it was uncertain whether 
this was a common feature of anti-malarial compounds 
or whether this phenomenon was restricted to these spe-
cific drugs. To assess whether iRBC rigidification was a 
universal outcome of anti-malarial drug treatment, the 
effect of 12 established anti-malarial compounds on 
iRBC deformability were systematically assessed. Purified 
iRBCs were incubated with drugs at a specific concentra-
tion (≥4 ×  EC50) for 4h and alteration in the biophysi-
cal characteristics of the cell were assessed by MFP. None 
of these anti-malarial compounds significantly altered 
the deformability of uninfected RBCs (Additional file  2: 
Figure S2). Suspensions of iRBCs in 0.001 % DMSO and 
ddH2O were used as baseline controls for this experi-
ment and there was no significant difference in median 
transit pressure between these control iRBCs. In contrast 
to untreated controls, a significant increase in median 
Fig. 1 Overview of the multiplexed fluidic plunger mechanism used 
to measure trophozoite‑infected red blood cells. a The microfluidic 
device measures ~40 mm by 20 mm and consists of a cell inlet and 
outlet reservoir, a long pressure attenuator and b deformability 
microarray, made up of a rectangular microchannel with 2 loading 
microchannels and 2 bypass microchannels surrounding 34 paral‑
lel deformation microchannels with a microconstriction width of 
~2.5 µm and a height of ~3.7 µm. RBCs are loaded into the deforma‑
tion microchannel under very low pressure. The pressure is then 
incrementally increased until the cell transits the microconstriction. 
c The pressure required for the trophozoite‑infected RBC (RBCs with 
a black pigment) to transit the microconstriction is indicative of the 
cell’s deformability [21]. d Giemsa‑stained blood smear confirming 
the pigmented iRBCs measured by the device are trophozoites
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transit pressure was observed for all drug-treated iRBCs, 
except tetracycline and the (−)-SJ733 enantiomer that 
serves as a negative control with no anti-malarial activity 
(Fig. 3, p < 0.001).
It was observed that the different anti-malarial com-
pounds had different effects on the deformability of 
iRBCs (Table  1). For example, while mefloquine and 
chloroquine are related compounds, mefloquine only 
reduced iRBC deformability by 22 %, while chloroquine 
induced 44 % reduction in iRBC deformability. Similarly, 
it was observed that each of the artemisinin derivatives 
induced significant rigidification of iRBCs and among 
them, dihydroartemisinin resulted in the least deform-
able iRBCs (111 %). The greatest rigidified iRBCs resulted 
from treatment with NITD 246 and the active (+)-SJ733 
enantiomer, showing 228 and 469 % loss in deformability, 
respectively, relative to the control (Fig. 3; Table 1).
Screen of bisindole alkaloid compounds for anti‑malarial 
activity
Collectively, these data suggested that iRBC rigidification 
could be an alternative method for anti-malarial drugs 
screening. Therefore, as a proof-of-principle, a group of 
bisindole alkaloid compounds were tested, which derive 
biosynthetically from the oxidative dimerization of tryp-
tophan [22–24] for their effects on iRBCs’ rigidification. 
Specifically, cladoniamide A, xenocladoniamide D, arcyr-
iaflavin A, and K252c were examined and it was observed 
that (Fig.  4a) cladoniamide A imparted 17  % greater 
rigidification of iRBCs than did chloroquine (Fig.  4b, 
p < 0.0001). Xenocladoniamide D and K252c resulted in a 
slight non-significant rigidification of iRBC relative to the 
DMSO control and arcyriaflavin A had no effect. None 
of these compounds affected the deformability of uRBCs 
(Additional file 3: Figure S3).
To assess whether the specific induced iRBC rigidi-
fication observed for cladoniamide A correlated with 
anti-malarial activity, an in  vitro SYBR-Green fluo-
rescence assay was performed to measure the effect of 
each drug on parasitaemia and generated dose response 
curves to determine the IC50 for each compound. Con-
sistent with the deformability analysis chloroquine 
(IC50  =  28  nM) and cladoniamide A (IC50  =  7.8  nM) 
displayed anti-malarial activity at a significantly lower 
dose than xenocladoniamide D (IC50  =  2.27  μM) and 
K252c (IC50 = 1.9 μM) (Fig. 4c). The anti-malarial activ-
ity of cladoniamide A has not been previously reported. 
However, it is interesting to note that cladoniamide A 
was recently reported to target a V-Type H+-ATPase in 
yeast [25]. In the Plasmodium parasite the V-type H+-
ATPase maintains the intracellular pH and disruption of 
this transporter contributes to acidification of the para-
site [25]. Another prominent anti-malarial drug target 
is PfATP4 which employs efflux to maintain a low para-
site intracellular Na+ concentration in Na+-rich blood. 
However, it has been reported that malaria V-Type H+-
ATPase activity is Na+-dependent, suggesting mecha-
nistic link between these transporters and PfATP4 
[26]. Together, these findings suggest that alterations in 
iRBC deformability correlate with anti-malarial activity. 
This rapid deformability-based screen was employed to 
identify the putative V-Type H+-ATPase inhibitor cla-
doniamide A as a compound with potent anti-malarial 
activity.
Fig. 2 Chloroquine exposure significantly decreases the deformability of trophozoites‑infected red blood cells in a dose‑ and time‑dependent 
manner. a Purified trophozoites were incubated with a range of chloroquine concentrations for 4 h. Each data point represents the transit pressure 
for one trophozoite iRBC and a significant increase in transit pressure was observed a 1 and 1.5 µM. b Purified trophozoites were incubated with 
1 µM chloroquine for at 2, 4 or 7 h. Treated and untreated iRBCs showed time‑dependent loss of deformability, with a significant increase in transit 
pressure by 4 h (p = 0.0026), compared to untreated iRBCs. c There is a positive correlation between the median transiting pressure of iRBCs incu‑
bated with (R2 = 0.9784) and without (R2 = 0.8946) chloroquine treatment and time of incubation
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Discussion
This study involved systematic assessment of the effect 
of established clinical and pre-clinical anti-malarial com-
pounds on the deformability of parasitized RBCs. It was 
observed that decrease in cell deformability was a com-
mon outcome of nearly all established anti-malarial com-
pounds tested. Furthermore, using specific reduced iRBC 
deformability as a biomarker for drug efficacy, cladon-
iamide A was identified as a candidate novel anti-malarial 
compound. Further investigation indicated that this com-
pound has an IC50 that is lower than chloroquine.
While most of the anti-malarial compounds examined in 
this study corresponded with a decrease in iRBC deform-
ability, they likely do so by distinct cellular mechanisms. 
The Plasmodium parasite metabolizes the haemoglobin 
of the host erythrocyte and generates toxic haem as a 
byproduct. Normally, the parasite detoxifies the host cell 
by biocrystallization of haem into haemozoin, but chloro-
quine inhibits this process and inhibits haem degradation 
to collectively contribute to the accumulation of haem 
within the host cell [27]. Intracellular haem contributes to 
oxidative stress in the iRBC, which is thought to be directly 
toxic to the parasite based on the observed sensitivity of P. 
falciparum to pro-oxidants [28], such as nitric oxide [29], 
hydrogen peroxide and superoxide [30]. Furthermore, 
oxidative stress contributes to reduced cell deformabil-
ity by membrane lipid peroxidation [11]. Also, quinoline 
anti-malarial drugs, such as chloroquine and mefloquine, 
induce haem association with the cell membrane, which 
further impairs the integrity of the membrane [28]. The 
observation that mefloquine has a more subtle impact on 
iRBC deformability than chloroquine is consistent with 
observation that mefloquine is a less effective inhibitor 
of haem degradation [28]. In contrast to the quinolone 
drugs, the mechanism for artesunate anti-malarial activity 
is not well established. However, artemisinin derivatives, 
such as artesunate, arthemether and dihydroartemisinin, 
are thought to be rapidly hydrolyzed or demethylated to 
their active metabolite, dihydroartemisinin [31, 32], which 
is therapeutically active against malaria infection [33]. 
Artemisinins may also target sarco/endoplasmic reticu-
lum Ca2+-ATPase, P. falciparum phosphatidylinositol-
3-kinase and haemoglobin digestion [34]. These cellular 
processes stimulate reactive oxygen species (ROS) that 
Fig. 3 Anti‑malarial drugs impair the deformability of trophozoite‑infected red blood cells. The deformability of purified trophozoite‑iRBCs was 
significantly diminished by treatment with all anti‑malarial drugs tested, except tetracycline. Treatment with the novel spiroindolone NITD246 
and DHIQ—(+) SJ733 showed the highest transiting pressure required for the iRBCs to squeeze through the microconstrictions of the device. 
**p < 0.001, ***p < 0.0001
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oxidize membrane thiols and contribute to reduced cellu-
lar deformability [12].
NITD 246 and the active (+)-SJ733 enantiomer induced 
the greatest rigidification of iRBCs. Both active molecules 
belong to the novel anti-malarial spiroindolone family that 
target PfATP4, a P-type ATPase [20, 35, 36]. The uptake of 
important nutrition by invading parasites allows Na+ influx 
and K+ efflux at the same time [36]. PfATP4, a parasite 
plasma membrane protein, helps intra-erythrocytic para-
sites maintain a low cytosolic Na+ by extruding Na+ against 
an inward gradient in exchange for H+ entry [36]. NITD246 
and (+)-SJ733 work as inhibitors of PfATP4 in nanomo-
lar concentrations and perturb efflux of Na+ and coupled 
influx of H+ by PfATP4 into the parasites, which increases 
both intracellular pH and sodium concentrations, resulting 
in parasite swelling and death [20, 36] as well as a spherical 
morphology of the RBC [20]. The (−)-SJ733 enantiomer was 
unable to reduce the deformability of iRBCs, consistent with 
its low potency against malaria in vitro [20] and highlights 
the specificity of the anti-malarial property to (+)-SJ733.
As a proof-of-principle, a group of bisindole alkaloid 
compounds were screened. Specifically, cladoniamide A, 
xenocladoniamide D, arcyriaflavin A, and K252c were 
examined. Cladoniamide A is a nanomolar cytotoxic 
agent, thought to target vacuolar H+-ATPase [25], xeno-
cladoniamide D is an inhibitor of the colon cancer cell line 
HCT-116 [23], arcyriaflavin A inhibits human cytomeg-
alovirus replication in vitro, and K252c inhibits many pro-
tein kinases, such as protein kinase C [37]. None of these 
compounds has been previously reported to have anti-
malarial properties and none of them affected the deform-
ability of uRBCs. The observation that cladoniamide A 
induces a dramatic rigidification of iRBCs and that this 
corresponds with a potent anti-malarial effect serves to 
support the hypothesis that reduced iRBC deformability 
is indicative of anti-malarial drug efficacy.
Fig. 4 ‘Mock’ drug screen shows the potential of cladoniamide A as an anti‑malarial. a Chemical structures of the bisindoles investigated in 
this study. b With reference to chloroquine, Bisindole compounds (1 µM each) exert differential effects on iRBC deformability. Cladoniamide A 
(p < 0.0001) and chloroquine (p = 0.0001) significantly decreased iRBC deformability and K252c and xenocladoniamide D treatment resulted in 
non‑significant reduction in deformability. c The in vitro sensitivity of cladoniamide compounds tested by the SYBR Green I assay. The IC50 was 
9.041 nM for cladoniamide A, 28.46 nM for chloroquine, 1.899 µM for K252c, and 2.271 µM for xenocladoniamide D
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Conclusion
These results suggest that specific rigidification of iRBCs 
is a feature common to the anti-malarial compounds 
tested. Moreover, the propensity for less deformable cells 
to be retained within the interendothelial clefts of the 
spleen [10], suggest that changes in iRBC deformabil-
ity may contribute to the mode of action of anti-malarial 
compounds. Support for this assertion can be drawn from 
studies where chloroquine-mediated changes in RBC 
deformability promote more rapid clearance of the rigid 
cells [14]. Furthermore, the observation that the spiroin-
dolones NITD246 and (+)-SJ733 induced the greatest 
magnitude of iRBC rigidification is consistent with obser-
vations that the primary mode of action for these PfATP4 
inhibitors is by host-mediated clearance [20]. The pro-
gressive rigidification of parasitized RBCs has previously 
been attributed to parasite-expressed factors as well as 
enhanced cell senescence and that rigid RBCs contribute 
to disease pathology through sequestration of these cells 
and obstruction of the microvasculature. However, obser-
vation that rigidification is a feature common to clini-
cal ant-malarial compounds tested here, suggest that its 
impact is primarily associated with clearance of infected 
RBCs by adsorption within the inter-endothelial clefts of 
the spleen. Finally, a small-scale screen of bisindole alka-
loids revealed that reduced RBC deformability could serve 
as a predictor of anti-malarial activity in a compound. 
Together, these data, as well as recently published data 
[38], suggest that reduced cell deformability can serve 
as a rapid and sensitive biomarker for anti-malarial drug 
efficacy. The ability to assess cell deformability using mas-
sively parallelized microfluidic systems without the need 
for expensive reagents, make such systems ideal for large-
scale anti-malarial drug screens.
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